Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials
Authors:
Open Access
- 14 June 2012
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 23 (11) , 2843-2851
Abstract
To evaluate whether medullary breast cancer has a better prognosis compared with invasive ductal tumors. Among 12 409 patients, 127 were recorded as invasive medullary tumors and 8096 invasive ductal tumors. Medullary and ductal invasive tumors were compared with regard to stage, age at diagnosis, grade, hormone receptor status, peritumoral vascular invasion, and local and systemic treatment. Pattern of relapse, distant recurrence-free interval (DRFI), and overall survival (OS) were determined for both histological groups. Two cohorts were investigated: a full cohort including the pathologist-determined medullary histology without regard to any other tumor features and a cohort restricted to patients with ER-negative grade 3 tumors. Fourteen-year DRFI and OS percents for medullary tumors (n = 127) and invasive ductal tumors (n = 8096) of the full cohort were 76% and 64% [hazard ratio (HR) 0.52, P = 0.0005] and 66% and 57% (HR = 0.75, P = 0.03), respectively. For the restricted cohort, 14-year DRFI and OS percents for the medullary (n = 47) and invasive ductal tumors (n = 1407) were 89% and 63% (HR 0.24, P = 0.002) and 74% and 54% (HR = 0.55, P = 0.01), respectively. Competing risk analysis for DRFI favored medullary tumors (HR medullary/ductal = 0.32; 95% confidence interval = 0.13–0.78, P = 0.01). Medullary tumors have a favorable prognosis compared with invasive ductal tumors.Keywords
Funding Information
- Ludwig Institute for Cancer Research
- Cancer League of Ticino
- Swedish Cancer Society
- Cancer Council Australia
- Australian New Zealand Breast Cancer Trials Group
- the Frontier Science and Technology Research Foundation
- Swiss Group for Clinical Cancer Research
- Swiss Cancer League
- United States National Institutes of Health (CA-75362)
This publication has 49 references indexed in Scilit:
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011Annals of Oncology, 2011
- Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancerAnnals of Oncology, 2011
- Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IXAnnals of Oncology, 2011
- The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breastEuropean Journal of Cancer, 2009
- Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a centuryBreast Cancer Research and Treatment, 2009
- Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93Breast Cancer Research and Treatment, 2008
- Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93Annals of Oncology, 2007
- Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entityBreast Cancer Research, 2007
- Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiationThe Journal of Pathology, 2006
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999